Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1973 1
1974 2
1975 1
1976 4
1977 2
1978 6
1979 8
1980 8
1981 8
1982 14
1983 10
1984 18
1985 15
1986 12
1987 23
1988 10
1989 4
1990 1
1991 7
1992 3
1993 6
1994 9
1995 3
1996 3
1997 5
1998 10
1999 12
2000 10
2001 7
2002 16
2003 15
2004 13
2005 10
2006 20
2007 12
2008 10
2009 16
2010 16
2011 16
2012 23
2013 18
2014 29
2015 49
2016 42
2017 44
2018 51
2019 48
2020 44
2021 58
2022 46
2023 42
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

786 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Malignant Lymphoid Neoplasm"
Page 1
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Cheah CY, Wei MC, Yin S, Li CC, Huang H, Kwan A, Penuel E, Bartlett NL. Budde LE, et al. Lancet Oncol. 2022 Aug;23(8):1055-1065. doi: 10.1016/S1470-2045(22)00335-7. Epub 2022 Jul 5. Lancet Oncol. 2022. PMID: 35803286 Clinical Trial.
BACKGROUND: Mosunetuzumab is a CD20 CD3 T-cell-engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells. In a phase 1 study, mosunetuzumab was well tolerated and active in patients with relapsed or refractory B-cell lymphoma. We, …
BACKGROUND: Mosunetuzumab is a CD20 CD3 T-cell-engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant …
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Jabbour E, et al. Lancet Haematol. 2023 Jan;10(1):e24-e34. doi: 10.1016/S2352-3026(22)00319-2. Epub 2022 Nov 16. Lancet Haematol. 2023. PMID: 36402146 Clinical Trial.
METHODS: We did a single-centre, single-arm, phase 2 study at the University of Texas MD Anderson Cancer Center, Houston, TX, USA, in patients aged 18 years or older with newly diagnosed or relapsed or refractory Ph-positive acute lymphoblastic leukaemia or chronic myeloid …
METHODS: We did a single-centre, single-arm, phase 2 study at the University of Texas MD Anderson Cancer Center, Houston, TX, USA, in patien …
Engineering the next generation of CAR-NK immunotherapies.
Biederstädt A, Rezvani K. Biederstädt A, et al. Int J Hematol. 2021 Nov;114(5):554-571. doi: 10.1007/s12185-021-03209-4. Epub 2021 Aug 28. Int J Hematol. 2021. PMID: 34453686 Free PMC article. Review.
Over the past few years, cellular immunotherapy has emerged as a novel treatment option for certain forms of hematologic malignancies with multiple CAR-T therapies now routinely administered in the clinic. ...Natural killer (NK) cells are part of the innate immune system w …
Over the past few years, cellular immunotherapy has emerged as a novel treatment option for certain forms of hematologic malignancies …
Cytokines in the Treatment of Cancer.
Conlon KC, Miljkovic MD, Waldmann TA. Conlon KC, et al. J Interferon Cytokine Res. 2019 Jan;39(1):6-21. doi: 10.1089/jir.2018.0019. Epub 2018 Jun 11. J Interferon Cytokine Res. 2019. PMID: 29889594 Free PMC article. Review.
Cytokine therapy to activate the immune system of cancer patients has been an important treatment modality and continues to be a key contributor to current clinical cancer research. Interferon alpha (IFNalpha) is approved for adjuvant treatment of completely resected high- …
Cytokine therapy to activate the immune system of cancer patients has been an important treatment modality and continues to be a key contrib …
Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma.
Lunning MA, Vose JM. Lunning MA, et al. Blood. 2017 Mar 2;129(9):1095-1102. doi: 10.1182/blood-2016-09-692541. Epub 2017 Jan 23. Blood. 2017. PMID: 28115369 Free article. Review.
Significant strides in the immunohistochemical and molecular signature of AITL have brought increased ability to diagnose this uncommon type of PTCL. The 2016 World Health Organization classification of lymphoid neoplasms recently acknowledged the complexity of this …
Significant strides in the immunohistochemical and molecular signature of AITL have brought increased ability to diagnose this uncommon type …
Primary mediastinal large B-cell lymphoma.
Savage KJ. Savage KJ. Blood. 2022 Sep 1;140(9):955-970. doi: 10.1182/blood.2020008376. Blood. 2022. PMID: 34496020 Free article.
However, given that 5% of DLBCL can have a molecular PMBCL phenotype in the absence of mediastinal involvement, clinical information remains critical for diagnosis. Studies during the past 10 to 20 years have elucidated the biologic hallmarks of PMBCL that are reminiscent …
However, given that 5% of DLBCL can have a molecular PMBCL phenotype in the absence of mediastinal involvement, clinical information …
Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM. Ansell SM. Am J Hematol. 2022 Nov;97(11):1478-1488. doi: 10.1002/ajh.26717. Epub 2022 Sep 19. Am J Hematol. 2022. PMID: 36215668 Free article.
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8540 new patients annually and representing approximately 10% of all lymphomas in the United States. ...For patients who fail HDCT with ASCT, brentuximab vedotin, PD-1 blocka …
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8540 new patients annually and rep …
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A, Soma L. Shustov A, et al. Cancer Treat Res. 2019;176:127-144. doi: 10.1007/978-3-319-99716-2_6. Cancer Treat Res. 2019. PMID: 30596216 Review.
Anaplastic Large Cell Lymphomas (ALCL) are clinically aggressive and pathologically distinct lymphoid neoplasms that originate from a mature post-thymic T-cell. The contemporary World Health Organization (WHO) Classification of Haematologic Malignancies recog …
Anaplastic Large Cell Lymphomas (ALCL) are clinically aggressive and pathologically distinct lymphoid neoplasms that originate …
Antibody therapeutics and immunoregulation in cancer and autoimmune disease.
Yasunaga M. Yasunaga M. Semin Cancer Biol. 2020 Aug;64:1-12. doi: 10.1016/j.semcancer.2019.06.001. Epub 2019 Jun 7. Semin Cancer Biol. 2020. PMID: 31181267 Free article. Review.
Among them, the anti-CD20 antibody has proven to be effective against both lymphoid malignancy and autoimmune disease. Moreover, immune checkpoint blockade using the anti-PD1/PD-L1/CTLA4 antibody has improved the prognosis of patients with refractory solid tu …
Among them, the anti-CD20 antibody has proven to be effective against both lymphoid malignancy and autoimmune disease. Moreove …
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.
Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Hüsser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umaña P. Bacac M, et al. Clin Cancer Res. 2018 Oct 1;24(19):4785-4797. doi: 10.1158/1078-0432.CCR-18-0455. Epub 2018 May 1. Clin Cancer Res. 2018. PMID: 29716920
Purpose: Despite promising clinical activity, T-cell-engaging therapies including T-cell bispecific antibodies (TCB) are associated with severe side effects requiring the use of step-up-dosing (SUD) regimens to mitigate safety. ...CD20-TCB displays considerably higher pote …
Purpose: Despite promising clinical activity, T-cell-engaging therapies including T-cell bispecific antibodies (TCB) are associated w …
786 results